Table 1.
Demographics and clinical characteristics of donors with clinically-defined PD, atypical parkinsonian disorders and donors without a definite clinical diagnosis.
| PD | Atypical parkinsonian disorders | No definite clinical diagnosis | |
|---|---|---|---|
| N | 176 | 101 | 16 |
| Sex M, n (%) | 104 (59%) | 61 (60%) | 11 (69%) |
| Age at onset y, mean ± SD (range), <50 / 50-75 / >75 y, n (%) | 62 ± 11 (32–88), 26/129/21 (15/73/12%) | 63 ± 9 (36–81), 8/84/9 (8/83/9%) | 66 ± 14 (34–84), 2/10/4 (13/63/25%) |
| Age at death y, mean ± SD (range) | 77 ± 8 (56–98) | 72 ± 9 (42–92)*** | 77 ± 11 (54–88) |
| Disease duration y, mean ± SD (range) | 15 ± 8 (2–42) | 8 ± 6 (0.5–38)*** | 11 ± 9 (3–41)* |
| Dementia, n (%) | 90 (51%) | 39 (39%)* | 4 (25%)* |
| Duration of dementia y, mean ± SD (range) | 4 ± 3 (0–12) | 2 ± 2 (0–10)*** | 4 ± 2 (2–5) |
| Visual hallucinations, n/N (%) | 95/121 (79%) | 22/28 (79%) | 0/6 (0%)*** |
| Rest tremor, n/N (%) | 120/143 (84%) | 38/68 (56%)*** | 10/14 (71%) |
| Clear response to dopaminergic therapy, n/N (%) | 118/135 (87%) | 12/55 (22%)*** | 3/12 (25%)*** |
| Positive family history of parkinsonism, n/N (%) | 33/86 (38%) | 14/60 (23%) | 2/8 (25%) |
| APOE ε4 alleles, n/N (%) | |||
| 0 | 78/115 (68%) | 48/80 (60%) | 9/11 (82%) |
| 1 | 33/115 (29%) | 29/80 (36%) | 2/11 (18%) |
| 2 | 4/115 (3%) | 3/80 (4%) | 0/11 (0%) |
| Specialization level of the diagnosing physician, n/N (%) | |||
| Movement disorders specialist | 59/144 (41%) | 52/95 (55%) | 6/14 (43%) |
| General neurologist | 76/144 (53%) | 37/95 (39%) | 4/14 (29%) |
| Non-neurologist | 9/144 (6%) | 6/95 (6%) | 4/14 (29%)** |
| Year of diagnosis, mean ± SD (range) | 1995 ± 10 (1970 – 2012) | 2002 ± 6 (1988 – 2014)*** | 1998 ± 10 (1979 – 2013) |
P-values are shown for comparisons between the PD group and the atypical parkinsonian disorders group or the group without a definite clinical diagnosis using t-tests for continuous variables and chi-square tests for categorical variables. * p < 0.05; ** p < 0.01; *** p < 0.001